Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
出版年份 2022 全文链接
标题
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
作者
关键词
-
出版物
LEUKEMIA & LYMPHOMA
Volume -, Issue -, Pages 1-12
出版商
Informa UK Limited
发表日期
2022-01-11
DOI
10.1080/10428194.2021.2020779
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Treatment of Chronic Lymphocytic Leukemia
- (2020) Jan A. Burger NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
- (2020) Inhye E. Ahn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
- (2019) John C. Byrd et al. BLOOD
- Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
- (2019) Thomas J. Kipps et al. Clinical Lymphoma Myeloma & Leukemia
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
- (2019) Kathrine Aarup et al. BLOOD
- Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results from the informCLL™ Registry
- (2019) Anthony R. Mato et al. Clinical Lymphoma Myeloma & Leukemia
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
- (2019) Jan A. Burger et al. LEUKEMIA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- NOTCH1 Aberrations in Chronic Lymphocytic Leukemia
- (2018) Emanuela Rosati et al. Frontiers in Oncology
- Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
- (2018) Anthony R. Mato et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2018) G. Fraser et al. LEUKEMIA
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
- (2017) J R Brown et al. LEUKEMIA
- Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia
- (2016) Preetesh Jain et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Mutations driving CLL and their evolution in progression and relapse
- (2015) Dan A. Landau et al. NATURE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
- (2015) P. Baliakas et al. BLOOD
- NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment
- (2014) Michele Dal Bo et al. ANNALS OF HEMATOLOGY
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
- (2014) D. Rossi et al. BLOOD
- Clinical implications of the molecular genetics of chronic lymphocytic leukemia
- (2013) R. Foa et al. HAEMATOLOGICA
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started